

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Tatsuya TAMURA et al.

Application No.: 09/700,879

Filed: November 20, 2000

For: CONJUGATE OF THERAPEUTIC AGENT FOR JOINT DISEASE AND HYALURONIC ACID

Art Unit:

Examiner:

Washington, D.C.

Atty.'s Docket: TAMURA=5

Date: February 6, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] SECOND PRELIMINARY AMENDMENT in the above-identified application.

[ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.  
 [ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.  
 [XX] No additional fee is required.

The fee has been calculated as shown below:

|   | (Col. 1)                                  | (Col. 2)                              | (Col. 3)                   |
|---|---|---------------------------------------|----------------------------|
|   | CLAIMS<br>REMAINING<br>AFTER<br>AMENDMENT | HIGHEST NO.<br>PREVIOUSLY<br>PAID FOR | PRESENT<br>EXTRA<br>EQUALS |
| TOTAL                                     | * 20                                      | MINUS                                 | ** 0                       |
| INDEP.                                    | * 2                                       | MINUS                                 | *** 0                      |
| FIRST PRESENTATION OF MULTIPLE DEP. CLAIM |   |                                       |                            |

ADDITIONAL FEE TOTAL \$

| SMALL ENTITY |                |
|--------------|----------------|
| RATE         | ADDITIONAL FEE |
| x 9          | \$             |
| x 40         | \$             |

OR

| OTHER THAN SMALL ENTITY |                |
|-------------------------|----------------|
| RATE                    | ADDITIONAL FEE |
| x 18                    | \$             |
| x 80                    | \$             |

OR

TOTAL \$

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

## Small Entity

## Response Filed Within

[ ] First - \$ 55.00  
 [ ] Second - \$ 195.00  
 [ ] Third - \$ 445.00  
 [ ] Fourth - \$ 695.00

## Month After Time Period Set

## Other Than Small Entity

## Response Filed Within

[ ] First - \$ 110.00  
 [ ] Second - \$ 390.00  
 [ ] Third - \$ 890.00  
 [ ] Fourth - \$ 1390.00

## Month After Time Period Set

[ ] Less fees (\$\_\_\_\_\_) already paid for \_\_\_\_ month(s) extension of time on \_\_\_\_\_.

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_.

[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$\_\_\_\_\_.


[ ] A check in the amount of \$\_\_\_\_\_ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Sheridan Neimark  
Registration No. 20,520Facsimile: (202) 737-3528  
Telephone: (202) 628-5197


1623  
0130  
O I P E J C 100  
P A T E N T & T R A D E M A R K O F F I C E 2001  
FEB 06 2001  
FEB 21 2001  
R E C E I V E D  
U S P T O W A S H I N G T O N , D . C .  
P R E P A R E D / J U N I S  
FEB 20 2001  
O I P E / J U N I S

RECEIVED

FEB 21 2001

TECH CENTER 1500  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE

ATTY. S DOCKET: TAMURA=5

In re Application of: ) Art Unit:  
Tatsuya TAMURA et al. )  
Appln. No.: 09/700,879 ) Examiner:  
Date Filed: November 20, 2000 ) Washington, D.C.  
For: CONJUGATE OF THERAPEUTIC ) February 6, 2001  
AGENT FOR JOINT DISEASE...



B15  
A.J.P  
3/20/01

SECOND PRELIMINARY AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

A review of the present application having revealed some typographical errors, please amend as follows:

IN THE CLAIMS

Using the new procedure for claim amending, please rewrite claims 1, 2, 4-10 and 11 (marked up copies of these claims are attached) as follows:

*Subj Cmt*

~~1. A conjugate of (1) at least one therapeutic agent for joint diseases and (2) hyaluronic acid, a hyaluronic acid derivative or a salt thereof.~~

*Ajt*

~~2. The conjugate of claim 1, wherein the bond between at least one therapeutic agent for joint diseases and~~